Fermenta Biotech Limited (FERMENTA)
₹486.00 -0.10% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Fermenta Biotech's revenue was ₹112 Cr (-6.0% year on year, +1.7% on the previous quarter), and net profit ₹15.0 Cr (-6.3% year on year); the operating margin was 20.5%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹112 | -6.0% | +1.7% |
| Operating profit | ₹23.0 | -0.1% | +4.4% |
| Net profit | ₹15.0 | -6.3% | -31.9% |
| EPS (₹) | 5.23 | -5.1% | -28.6% |
| Operating margin | 20.5% | — | — |
FERMENTA delivery percentage and bulk deals
NSE end-of-day data for
On Fri, 16 Oct 2026, 42.76% of the FERMENTA shares traded on NSE were taken to delivery, against the stock's own 20-session average of 45.4%. That is close to its usual level. Volume was 0.1 times its average, well below normal. 7 bulk or block deals were reported in FERMENTA in the last 60 days: ₹40 Cr bought and ₹73 Cr sold.
Delivery in the last 5 sessions: 44.1% · 43.2% · 48.6% · 59.1% · 42.8%
| Date | Side | Counterparty | Value | Price | Quantity | Type |
|---|---|---|---|---|---|---|
| 29 Sep | Sell | Alphagrep Securities Private Limited | ₹9.14 Cr | ₹547.97 | 166,836 | Bulk |
| 29 Sep | Buy | Alphagrep Securities Private Limited | ₹9.14 Cr | ₹547.61 | 166,836 | Bulk |
| 29 Sep | Sell | Qe Securities Llp | ₹8.06 Cr | ₹547.11 | 147,373 | Bulk |
| 29 Sep | Buy | Qe Securities Llp | ₹7.94 Cr | ₹551.69 | 143,855 | Bulk |
| 28 Sep | Sell | Thakkar Preeti | ₹55.34 Cr | ₹474.65 | 1,165,938 | Bulk |
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Fermenta Biotech Limited submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the period ended September 30, 2026. The confirmation, issued by Registrar and Transfer Agent MUFG Intime India Pvt. Ltd. on October 7, 2026, certifies that all physical share certificates received for dematerialisation were processed, verified, and cancelled within prescribed timelines. The RTA also noted that zero rematerialization requests were received during the quarter. This is a recurring regulatory disclosure with no impact on operations or financials.
- Compliance certificate submitted for the quarter ended September 30, 2026
- RTA confirmation issued by MUFG Intime India Pvt. Ltd. dated October 7, 2026
- Confirmation that zero requests were received for rematerialization during the quarter
- Filing submitted to BSE and NSE on October 08, 2026
Fermenta Biotech Limited has informed the exchanges that its officials will participate in a physical one-to-one investor meeting in Mumbai on September 22, 2026. The discussions will be based on already public press releases and investor presentations, with no unpublished price-sensitive information (UPSI) shared. In its latest reported quarter (Jun 2026), the company posted revenue of Rs 111.84 cr and net profit of Rs 14.99 cr. This disclosure is a standard regulatory intimation under Regulation 30 of SEBI LODR.
- One-to-one investor meeting scheduled for September 22, 2026
- Meeting to be held physically in Mumbai
- No unpublished price sensitive information (UPSI) will be discussed
- Jun 2026 quarterly revenue stood at Rs 111.84 cr with net profit of Rs 14.99 cr
Fermenta Biotech Limited has dispatched reminder letters to shareholders who have not claimed dividends for seven consecutive years starting from the FY 2019-20 interim dividend. Concerned shareholders must submit their claims on or before November 18, 2026. Failing this, the underlying shares and unpaid dividends will be transferred to the Investor Education and Protection Fund (IEPF) Demat Account under Section 124(6) of the Companies Act, 2013.
- Notice dispatched on September 16, 2026 to shareholders with unclaimed dividends for 7 consecutive years.
- Deadline set to November 18, 2026 for shareholders to claim unpaid dividends before shares transfer to IEPF.
- Applies to unpaid interim dividends starting from the financial year 2019-20.
- Action mandated under Section 124(6) of the Companies Act, 2013 and IEPF Rules, 2016.
Fermenta Biotech Limited has signed an exclusive licensing agreement with Vellore Institute of Technology (VIT) for commercialising an in-situ Vitamin B12 fortification technology in fermented foods (Indian Patent Application No. 202441015300). Lab studies indicated approximately 80% retention of Vitamin B12 post-cooking. Financial terms, including licensing fees or commercialization royalty figures, were not disclosed. The development represents an early-stage technological expansion of Fermenta's nutritional premix and food fortification portfolio.
- Exclusive licence agreement with VIT Vellore for Vitamin B12 fortification technology covered under Indian Patent Application No. 202441015300
- Laboratory studies demonstrated approximately 80% retention of enhanced Vitamin B12 post-cooking
- Financial licensing fees, royalty rates, and commercialisation capex are not disclosed
- Company reported Jun 2026 quarterly revenue of ₹111.84 cr and net profit of ₹14.99 cr
Fermenta Biotech Limited resubmitted its standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, in a machine-readable format following an exchange query. The company had initially approved and reported these results on August 11, 2026. For Q1 FY27, standalone revenue from operations stood at ₹11,183.93 lakhs (down 6.0% YoY from ₹11,901.87 lakhs), while standalone net profit was ₹1,498.58 lakhs compared to ₹1,623.38 lakhs in the corresponding prior-year period. Statutory auditors M/s SRBC & Co. LLP issued a limited review report with an unmodified conclusion.
- Resubmission of Q1 FY27 financial results in machine-readable format as requested by the exchange on September 03, 2026
- Standalone revenue from operations reported at ₹11,183.93 lakhs for the quarter ended June 30, 2026 (vs ₹11,901.87 lakhs in Q1 FY26)
- Standalone profit after tax stood at ₹1,498.58 lakhs with basic EPS of ₹5.23 per share of ₹5 face value
- Company granted 3,95,400 employee stock options at an exercise price of ₹83.67 per option during the quarter
- Auditor SRBC & Co. LLP issued an unmodified review conclusion on both standalone and consolidated results
Fermenta Biotech Limited has informed the stock exchanges that company officials will participate in physical one-on-one investor meetings in Mumbai on September 3, 2026. The company stated that discussions will be based on already published press releases and investor presentations available in the public domain. No unpublished price sensitive information (UPSI) will be shared during the interaction.
- Investor meeting scheduled for September 3, 2026 in Mumbai
- Format is physical one-to-one meeting(s)
- No unpublished price sensitive information (UPSI) to be shared
- Discussions to rely on existing public presentations and filings
Fermenta Biotech Limited has informed the exchanges regarding a scheduled one-to-one physical meeting with investor(s) on August 21, 2026, in Mumbai. The company clarified that discussions will rely on publicly available presentations and press releases, with no unpublished price-sensitive information (UPSI) shared. In its latest reported quarter (June 2026), the company posted revenue of ₹111.84 cr and a net profit of ₹14.99 cr.
- One-to-one physical investor meeting scheduled for August 21, 2026, in Mumbai
- Company confirmed no Unpublished Price Sensitive Information (UPSI) will be discussed
- Latest June 2026 quarter reported revenue of ₹111.84 cr and PAT of ₹14.99 cr
Fermenta Biotech Limited has received a credit rating upgrade from CARE Ratings Limited across its bank facilities totaling Rs 172.98 crore. Long-term bank facilities of Rs 166.73 crore (enhanced from Rs 118.94 crore) were upgraded to CARE BBB+; Stable from CARE BBB; Stable. Short-term bank facilities of Rs 6.25 crore were upgraded to CARE A2 from CARE A3+. The rating enhancement indicates improved operational and credit profile, potentially aiding in better borrowing terms.
- Long-term bank facilities rating upgraded to CARE BBB+; Stable from CARE BBB; Stable
- Long-term bank facilities limit enhanced to Rs 166.73 crore from Rs 118.94 crore
- Short-term bank facilities of Rs 6.25 crore upgraded to CARE A2 from CARE A3+
- Total rated bank facilities increased to Rs 172.98 crore
Fermenta Biotech Limited held its 74th Annual General Meeting on August 11, 2026, where shareholders approved a dividend of ₹3.75 per share (75% of face value). A key resolution passed includes the approval of material related party transactions with its step-down subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crores. The company also authorized the payment of commissions to non-executive directors, capped at 1% of net profits. All proposed resolutions, including the re-appointment of Director Ms. Rajeshwari Datla, were passed with the requisite majority.
- Approved a dividend of ₹3.75 per equity share (75% of ₹5 face value) for FY 2025-26.
- Authorized material related party transactions with Fermenta USA LLC up to a limit of ₹100 crores.
- Capped commissions for Non-Executive Directors at 1% of the company's net profits.
- Set the dividend payment deadline for on or before August 21, 2026.
- Confirmed the re-appointment and continuation of Ms. Rajeshwari Datla as a Non-Executive Director.
Fermenta Biotech Limited held its 74th Annual General Meeting on August 11, 2026, where shareholders approved a dividend of ₹3.75 per share (75% of face value) for FY26. A significant resolution was passed for material related party transactions with its step-down subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crores. The board also received approval to distribute commissions to Non-Executive Directors up to 1% of net profits. The dividend is scheduled for payment by August 21, 2026, to shareholders on record as of August 05, 2026.
- Approved dividend of ₹3.75 (75%) per equity share of ₹5 face value for FY2025-26.
- Authorized material related party transactions with Fermenta USA LLC up to ₹100 crores.
- Approved commission for Non-Executive Directors up to 1% of the company's net profits.
- Dividend payment to be completed on or before August 21, 2026.
- Re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director confirmed by special resolution.
Fermenta Biotech Limited concluded its 74th Annual General Meeting on August 11, 2026, with shareholders approving all proposed resolutions with overwhelming majorities. A key highlight is the approval of a Rs 3.75 per equity share dividend (75% of face value) for FY26. Shareholders also ratified the audited standalone and consolidated financial statements for the year ended March 31, 2026. Additionally, approval was granted for material related party transactions and the re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director.
- Dividend of Rs 3.75 per equity share (75% of Rs 5 face value) approved for FY26.
- Material Related Party Transactions resolution passed with 99.9763% votes in favor.
- FY26 Standalone and Consolidated Financial Statements adopted with 99.9999% shareholder approval.
- Re-appointment of Ms. Rajeshwari Datla as Director approved with 99.9980% majority.
- AGM conducted virtually, concluding at 5:12 p.m. IST on August 11, 2026.
Fermenta Biotech reported a weak YoY performance for Q1 FY27, with PAT falling 56% to INR 9.5 crore, largely due to a high base in Q1 FY26 which included non-recurring income. Revenue stood at INR 126.2 crore, down 13% YoY, though the Human Nutrition segment showed sequential recovery with 24% QoQ growth to INR 76.5 crore. The company is pivoting toward the domestic market, with India now contributing 47% of revenue compared to 35% a year ago. Animal nutrition remains a significant drag, with volumes down 52% QoQ as the company maintained volume discipline against a 40% drop in realizations.
- Human Nutrition revenue grew 24% QoQ to INR 76.5 crore, with segment volumes increasing 18% QoQ.
- Animal Nutrition revenue fell 41% YoY to INR 12.6 crore, impacted by a 40% drop in average realizations.
- India's share of consolidated revenue increased to 47% in Q1 FY27 from 35% in Q1 FY26.
- Raw material costs improved to 35% of revenue, down from 37% in FY26 and 38% in FY25.
- Employee costs rose to 19% of revenue from 16% in FY26, reflecting capacity expansion ahead of Dahej scale-up.
Fermenta Biotech reported a 56% YoY decline in consolidated Profit After Tax (PAT) to ₹9.5 crore for Q1FY27, primarily due to a high base in the previous year and a 40% drop in Vitamin D3 Animal Nutrition realizations. Consolidated revenue stood at ₹126.2 crore, down 13% YoY but flat sequentially. A key positive is the 18% sequential volume growth in the Human Nutrition segment and the recent FSSAI approval for VITADEE Green®. The company is also seeing a shift in geographical mix, with India now contributing 47% of revenue compared to 35% a year ago.
- Consolidated PAT fell 56% YoY to ₹9.5 crore, impacted by a 40% drop in Animal Nutrition realizations.
- Human Nutrition volumes grew 18% sequentially, with the segment contributing ₹76.5 crore to revenue.
- India's share of consolidated revenue increased to 47% from 35% in the previous year.
- VITADEE Green® received FSSAI approval on July 6, 2026, for use in health supplements and food fortification.
- Consolidated EBITDA (including real estate) was ₹22.4 crore, down 39% YoY and 11% QoQ.
Fermenta Biotech Limited's Board of Directors met on August 11, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The statutory auditors, M/s. SRBC & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no significant accounting irregularities were identified. The board meeting lasted 2 hours and 10 minutes. While the specific P&L figures were not detailed in this cover letter, the filing confirms the completion of the mandatory quarterly reporting cycle.
- Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026
- Statutory auditors SRBC & Co. LLP issued an unmodified opinion on the financial results
- Board meeting commenced at 11:00 a.m. and concluded at 01:10 p.m. on August 11, 2026
- The filing was made pursuant to Regulations 30 and 33 of SEBI Listing Regulations
Fermenta Biotech Limited has announced a physical one-to-one meeting with investors scheduled for August 17, 2026, in Mumbai. The company clarified that no unpublished price sensitive information (UPSI) will be shared, and discussions will focus on publicly available information. This meeting follows a significant 91.5% price appreciation in the stock over the last three months. Such interactions are standard procedural disclosures under SEBI Regulation 30.
- One-to-one physical meeting scheduled for August 17, 2026, in Mumbai
- Announcement issued on August 10, 2026, providing 7 days of advance notice
- Stock has delivered a 91.5% price return over the last 3 months
- Company confirms no unpublished price sensitive information (UPSI) will be discussed
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
